BioWorld

April 19, 2002

View Archived Issues

Trimeris, Roche Fusion Inhibitor Succeeds In Phase III HIV Trial

A fusion inhibitor for HIV patients being developed by Trimeris Inc. and Hoffmann-La Roche Inc. produced better than expected results in a Phase III trial. (BioWorld Today) Read More

Lynx Raises $22.6M, Cuts Staff By 30 Percent To Focus Efforts

Read More

Mammals, Research Nematodes Share Proteins Crucial For Stress Response, Mammalian Life Spans

Read More

Senesco Using Funding To Move Plant Technology Into Humans

Read More

Other News To Note

Read More